摘要
目的探讨达格列净(dapagliflozin,DAPA)联合二甲双胍(metformin,MET)对2型糖尿病(type 2 diabetes mellitus,T2DM)患者血糖控制、血脂代谢及用药安全性的影响,为临床优化治疗方案提供依据。方法回顾性选取2022年6月—2025年6月青岛市胶州中心医院就诊的100例T2DM患者的临床资料,按不同治疗方法分组。对照组(n=50)接受MET治疗,观察组(n=50)采用DAPA联合MET治疗。对比两组血糖、血脂水平及不良反应发生率。结果治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白及高密度脂蛋白水平均优于对照组,差异均有统计学意义(P均<0.05)。观察组不良反应发生率略高于对照组,但差异无统计学意义(P>0.05)。结论DAPA联合MET可改善T2DM患者的血糖及血脂代谢,且未增加严重不良反应发生风险,临床应用安全性可控。
Objective To investigate the effects of dapagliflozin(DAPA)combined with metformin(MET)on blood glucose control,lipid metabolism and drug safety in patients with type 2 diabetes mellitus(T2DM),and to provide a basis for clinical optimization of treatment.Methods The clinical data of 100 patients with T2DM who were treated in Qingdao Jiaozhou Central Hospital from June 2022 to June 2025 were retrospectively selected and grouped according to different treatment methods.The control group(n=50)was treated with MET,and the observation group(n=50)was treated with DAPA combined with MET.The blood glucose,blood lipid levels and incidence of adverse reactions were compared between the two groups.Results After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,total cholesterol,triglyceride,low density lipoprotein and high density lipoprotein in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the observation group was slightly higher than the control group,but the difference was not statistically significant(P>0.05).Conclusion DAPA combined with MET can improve blood glucose and lipid metabolism in patients with T2DM,and does not increase the risk of serious adverse reactions.The clinical application safety is controllable.
作者
孙浩
孙莉
张宏泽
SUN Hao;SUN Li;ZHANG Hongze(Department of Clinical Pharmacy,Qingdao Jiaozhou Central Hospital,Qingdao 266300,Shandong,China;Department of Endocrinology and Hematology,Qingdao Jiaozhou Central Hospital,Qingdao 266300,Shandong,China;Department of Neurology,Qingdao Jiaozhou Central Hospital,Qingdao 266300,Shandong,China)
出处
《糖尿病新世界》
2025年第21期117-120,共4页
Diabetes New World
关键词
2型糖尿病
达格列净
二甲双胍
血糖控制
血脂代谢
不良反应
Type 2 diabetes mellitus
Dapagliflozin
Metformin
Glycaemic control
Lipid metabolism
Adverse reactions
